/
Other
Erectile Dysfunction
30
Pipeline Programs↗
37
Active Trials↗
38
Companies Involved↗
Erectile Dysfunction is an emerging landscape with 30 programs across 38 companies. The most active players are Supernus Pharmaceuticals, Inc.. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical25
Phase 1
No programs
Phase 33
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
23 of 26 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 90% of 30 pipeline programs.
Analysis
Trial Status
219
clinical trials
Completed145 · 66%
Unknown status26 · 12%
Recruiting20 · 9%
Not yet recruiting10 · 5%
Active, not recruiting6 · 3%
Terminated6 · 3%
Other6 · 3%
Clinical Trials
Trial Activity
219 trials
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)